在服用抗糖尿病药物的成年人中,不受控制的糖尿病中存在种族和种族差异
Kristen A Berg1, Nazleen Bharmal2, Larisa G Tereshchenko3
1Center for Health Care Research and Policy, Population Health Research Institute, The MetroHealth System at Case Western Reserve University, Cleveland, OH, USA.
Primary care diabetes
|February 29, 2024
概括
在服用药物的患者中,对2型糖尿病 (T2DM) 控制的种族和种族差异仍然存在. 即使考虑到其他健康和社会经济因素,这些差异仍然很大,凸显了持续的健康不平等.
科学领域:
- 公共卫生 公共卫生
- 流行病学 流行病学
- 健康差异 在健康上的差异
背景情况:
- 2型糖尿病 (T2DM) 影响全球数以百万计的人,在不同种族和民族群体的管理和结果中存在显著差异.
- 了解T2DM控制中的持续差异对于开发有针对性的干预措施至关重要.
研究的目的:
- 调查是否在未经控制的T2DM中存在种族和种族差异,在使用药物的患者中持续存在.
- 为了确定这些差异是否在调整人口,社会经济和健康指标后仍然存在.
主要方法:
- 使用2007-2018年国家健康和营养检查调查 (NHANES) 数据进行的回顾性队列研究.
- 纳入标准:年龄≥20岁的T2DM成年人处方药.
- 分析:加权序列多变量逻辑回归模型,以评估不受控制的T2DM (HbA1c ≥ 8%) 的几率,按种族/民族分类.
主要成果:
- 在接受药物治疗的3649名T2DM患者中,有27.4%的人患有不受控制的糖尿病 (HbA1c ≥8%).
- 与非西班牙裔白人相比,非西班牙裔黑人 (OR 1.38) 和西班牙裔 (OR 1.79) 个体中不受控制的T2DM更为普遍,即使在调整后.
- 在T2DM控制中的这些差异在种族和种族群体中持续存在.
结论:
- 在接受药物治疗的患者中,T2DM控制的种族和种族差异明显.
- 对发育和表观遗传因素的进一步研究可能会揭示少数群体中T2DM控制差异的途径.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
Diabetes: Symptoms, Diagnosis, and Complications
534
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
534
Diabetes Mellitus: Overview and Type I Subtype
2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K
Diabetes: Management and Pharmacotherapy
282
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
282
Pathophysiology of Diabetes
928
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
928
Insulin: Dosing Regimen and Adverse Effects
170
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
170


